Catherine Skari
-
Mar- 2021 -2 MarchNews
TIF’s Submission To The UK NICE’s Consultation Document For Zynteglo®
On February 12, in an appraisal consultation document, the UK National Institute for Health and Care Excellence (NICE) recommended against the use…
Read More » -
Feb- 2021 -24 FebruaryNews
Time To Get Ready For Rare Disease Day 2021!
TIF joins forces with 300 million people around the world for the global observance of Rare Disease Day, coming up…
Read More » -
20 FebruaryNews
TIF’s Public Statement on Current Developments in Gene Therapy SCD Clinical Trials and Thalassaemia Gene Therapy Zynteglo
The Thalassaemia International Federation (TIF) has been informed through official communication by both the European Medicines Agency (EMA) and bluebird…
Read More » -
16 FebruaryNews
NOW PUBLISHED: The TIF ‘’Gene Therapy & Thalassaemia’’ Survey Report
Gene therapy for thalassaemia is an expensive and complex procedure, with great efforts ongoing currently by all involved stakeholders, such…
Read More » -
3 FebruaryNews
The Lancet: Russian Coronavirus Sputnik V Vaccine Achieves Over 90% Efficacy
Russia’s Sputnik V vaccine was 91.6% effective in preventing people from developing Covid-19, according to peer-reviewed results from its late-stage…
Read More » -
2 February
-
Jan- 2021 -31 JanuaryNews
EMA Accepts MAA For Oxbryta To Treat Haemolytic Anaemia In Sickle Cell Disease
The European Medicines Agency (EMA) has accepted Global Blood Therapeutics (GBT) marketing authorisation application (MAA) for Oxbryta® (voxelotor) for the treatment…
Read More » -
29 JanuaryNews
TIF Updated Vaccinations & Therapeutic Drugs COVID-19 Guide Has Landed
A comprehensive Guide for both existing and developing vaccines and treatments against COVID-19, exclusively developed by TIF for its global…
Read More » -
28 JanuaryTIF News
WHO Maintains Official Relations With TIF For 2021-2024
We are very proud to inform you that TIF remains in official relations with the World Health Organization (WHO) for…
Read More » -
22 JanuaryClinical News
Clinical Trial Cleared for GPH101: The First Potentially Curative Sickle Cell Disease Therapy
The U.S. Food & Drug Administration (FDA) has cleared an investigational new drug (IND) application for the experimental gene editing…
Read More »
